The incorporation of novel agents such as bortezomib and lenalidomide into initial therapy
for multiple myeloma has improved the response rate of induction regimens. Also, these …

The outcomes and management of multiple myeloma (MM) in the United States have
changed dramatically over the past 15 years with the approval by the US Food and Drug …

Current standards of care for first-line treatment of multiple myeloma are evolving rapidly
because of the introduction of regimens based on novel agents with unique mechanisms of …

Recent developments in the treatment of multiple myeloma have led to improvements in
response rates and to increased survival; however, relapse is inevitable in almost all …

Despite significant progress in the treatment of multiple myeloma (MM) over the past
decade, this disease remains incurable and almost all patients ultimately experience …

Despite the development of more effective therapies for multiple myeloma (MM) over the
past decade, nearly all patients will eventually experience disease relapse and require …

Over two-thirds of newly diagnosed multiple myeloma are over 65 years. The treatment
goals for the non-transplant-eligible patients should be to prolong survival by achieving the …

The introduction of the Immunomodulatory drugs (IMiDs) and proteasome inhibitors, used
either as a single-agent or combined with classic anti-myeloma therapies, has improved the …

Remarkable progress has been achieved in multiple myeloma, and patient median survival
has been extended 3-to 4-fold. Specifically, there have been 18 newly approved treatments …

A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …